GAA
CSTL icon

Green Alpha Advisors’s Castle Biosciences CSTL Stock Holding History

Green Alpha Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$244K Sell
9,945
-291
-3% -$9.53K 0.24% 84
2025
Q4 		$398K Buy
10,236
+698
+7% +$22.5K 0.36% 83
2025
Q3 		$217K Buy
+9,538
New +$194K 0.21% 88
2025
Q1 		– Sell
-9,327
Closed -$249K – 121
2024
Q4 		$249K Buy
+9,327
New +$284K 0.2% 120

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Green Alpha Advisors's CSTL Position: Q1 2026 in Review

Green Alpha Advisors reduced its Castle Biosciences (CSTL) stake by 2.8% in Q1 2026, selling an estimated $9.53K and leaving 9,945 shares worth $244K. The position accounts for 0.24% of the portfolio, ranked #84.

Green Alpha Advisors first reported a position in CSTL in Q4 2024 and has held it in 4 quarters since. The position peaked at $398K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Green Alpha Advisors held 9,945 shares of Castle Biosciences worth $244K as of Q1 2026.
  • Green Alpha Advisors sold 291 Castle Biosciences shares in Q1 2026, an estimated $9.53K.
  • Castle Biosciences made up 0.24% of Green Alpha Advisors's portfolio in Q1 2026, its #84 holding.
  • Green Alpha Advisors first reported a position in Castle Biosciences in Q4 2024 and has held it in 4 quarters since.
  • Green Alpha Advisors's Castle Biosciences position peaked at $398K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Green Alpha Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.